Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 11/20 | 0.65 |
| ▸ | RAB9A | P51151 | 11/20 | 0.65 |
| ▸ | PKM | P14618 | 5/20 | 0.65 |
| ▸ | MAOB | P27338 | 3/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.61 |
| ▸ | SCD | O00767 | 1/20 | 0.59 |
| ▸ | KLF5 | Q13887 | 2/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL861789 | 0.85 | HPSE (0.52) | PRMT5NPC1RAB9APKMMAOB | |
| SCHEMBL29066590 | 0.81 | LMNA (0.60) | PRMT5KDM4EKMT2A | |
| SCHEMBL4405834 | 0.81 | NPC1 (0.58) | PRMT5NPC1RAB9APKMMAOB | |
| SCHEMBL4316866 | 0.80 | ALDH1A1 (0.67) | PRMT5NPC1RAB9APKMSMN1; SMN2 | |
| SCHEMBL6244081 | 0.79 | PRMT5 (1.00) | PRMT5NPC1RAB9AKDRMEN1 | |
| SCHEMBL3926899 | 0.79 | NPC1 (1.00) | NPC1RAB9APKMMAOBADORA2A | |
| SCHEMBL12807020 | 0.77 | HPSE (0.48) | PRMT5TP53KMT2AMAPT | |
| SCHEMBL27593194 | 0.77 | ALDH1A1 (0.49) | PRMT5SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL11703118 | 0.76 | MAOB (0.71) | NPC1RAB9APKMMAOBADORA2A | |
| SCHEMBL6118295 | 0.76 | MAOB (0.71) | NPC1RAB9APKMMAOBADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207340-B2 | Imidazopyridinyl benzamide mitotic kinesin inhibitors | CYTOKINETICS, INCORPORATED (US) | 2012-06-26 | — | — | US | disclosed |
| US-8163919-B2 | Imidazopyridinyl benzamide mitotic kinesin inhibitors | CYTOKINETICS, INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-8067599-B2 | Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090318428-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | HOFFMANN-LA ROCHE, INC. | 2009-12-24 | — | — | US | disclosed |
| EP-2064213-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008028617-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318428-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | MAP3K5, MAP3K1, PRKACA | PRMT5 573/4885NPC1 1424/4885RAB9A 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.